In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 3, 2011, Pages 1422-1430

  Shafiee, Afshin ^a   Bucolo, Claudio ^a,b   Budzynski, Ewa ^a,c   Ward, Keith W ^a   López, Francisco J ^a,d  

^a BAUSCH AND LOMB   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

^c Acucela Inc   (United States)

^d Corning Incorporated ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; BOL 303242X; CYCLOSPORIN A; DEXAMETHASONE; DRUG VEHICLE; MAPRACORAT; PROSTAGLANDIN E2; PROTEIN; REFRESH ENDURA; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ZK 245186;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; DRY EYE; EYE DISEASE; EYE EXAMINATION; EYE INFLAMMATION; FEMALE; IN VIVO STUDY; INTRAOCULAR PRESSURE; LACRIMAL FLUID; NONHUMAN; PARACENTESIS; PRIORITY JOURNAL; RABBIT; TEAR BREAKUP TIME;

ADMINISTRATION, TOPICAL; ANIMALS; AQUEOUS HUMOR; BENZOFURANS; BODY WEIGHT; DEXAMETHASONE; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRY EYE SYNDROMES; FEMALE; GLUCOCORTICOIDS; INTRAOCULAR PRESSURE; PENTANOLS; QUINOLINES; RABBITS; RECEPTORS, GLUCOCORTICOID; TEARS; TREATMENT OUTCOME;

EID: 79955943211     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5598     Document Type: Article

References (55)

1. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev. 2004;125:697-706.
2. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids- new mechanisms for old drugs. N Engl J Med. 2005;353: 1711-1723.
3. Ronacher K, Hadley K, Avenant C, et al. Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction. Mol Cell Endocrinol. 2009;299:219-231.
4. Dell SJ, Shulman DG, Lowry GM, Howes J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis: Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol. 1997;123: 791-797.
5. Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis: the Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol. 1997;123:455-464.
6. Group LEUUS. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol. 1999;127:537-544.
7. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005; 112:1192-1198.
8. Butrus S, Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am. 2005;18:485-492.
9. Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol. 2007;7:429-435.
10. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology. 1999;106:811-816.
11. Barabino S, Dana MR. Dry eye syndromes. Chem Immunol Allergy. 2007;92:176-184.
12. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007;5:75-92.
13. Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol. 2005; 40:598-604.
14. Bhavsar AR. Diabetic retinopathy: the latest in current management. Retina. 2006;26:S71-S79.
15. Bhavsar AR, Tornambe PE. 25 years of progress in the treatment of retinal diseases: where we have been, where we are now, and where we will be. Retina. 2006;26:S1-S6.
16. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533-1538.
17. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.
18. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309-317.
19. Silva PS, Sun JK, Aiello LP. Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy. Semin Ophthalmol. 2009;24:93-99.
20. Stewart R, Horwitz B, Howes J, Novack GD, Hart K. Doublemasked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation: Loteprednol Etabonate Postoperative Inflammation Study Group 1. J Cataract Refract Surg. 1998;24:1480-1489.
21. Struck HG, Bariszlovich A. Comparison of 0.1% dexamethasone phosphate eye gel (Dexagel) and 1% prednisolone acetate eye suspension in the treatment of post-operative inflammation after cataract surgery. Graefes Arch Clin Exp Ophthalmol. 2001;239: 737-742.
22. Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008;92:455-459.
23. Rizzo G, Fiorucci S. PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol. 2006;6:421-427.
24. Sullivan DA, Schaumberg DA, Suzuki T, et al. Sex steroids, meibomian gland dysfunction and evaporative dry eye in Sjogren's syndrome. Lupus. 2002;11:667.
25. Chen HT, Chen KH, Hsu WM. Toxic keratopathy associated with abuse of low-dose anesthetic: a case report. Cornea. 2004;23:527-529.
26. Sullivan BD, Evans JE, Dana MR, Sullivan DA. Influence of aging on the polar and neutral lipid profiles in human meibomian gland secretions. Arch Ophthalmol. 2006;124:1286-1292.
27. McCulley JP, Aronowicz JD, Uchiyama E, Shine WE, Butovich IA. Correlations in a change in aqueous tear evaporation with a change in relative humidity and the impact. Am J Ophthalmol. 2006;141:758-760.
28. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10:505-512.
29. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23-43.
30. Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. Drugs Aging. 1999;15:439-450.
31. Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163-167.
32. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye. 2006;20:407-416.
33. Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009;116:652-657.
34. Schacke H, Zollner TM, Docke WD, et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol. 2009;158:1088-1103.
35. Zhang JZ, Cavet ME, Vandermeid KR, Salvador-Silva M, Lopez FJ, Ward KW. BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells. Mol Vis. 2009;15:2606-2616.
36. Pfeffer BA, Dewitt CA, Salvador-Silva M, Cavet M, López FJ, Ward KW. A selective glucocorticoid receptor agonist (SEGRA) induces decreased myocilin protein and gene expression in cultured monkey trabecular meshwork cells when compared with traditional ocular steroids. Invest Ophthalmol Vis Sci. 2009;51:437-446.
37. Burgalassi S, Panichi L, Chetoni P, Saettone MF, Boldrini E. Development of a simple dry eye model in the albino rabbit and evaluation of some tear substitutes. Ophthalmic Res. 1999;31:229-235.
38. Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21:221-232.
39. Williams RN, Paterson CA, Eakins KE, Bhattacherjee P. Quantification of ocular inflammation: evaluation of polymorphonuclear leucocyte infiltration by measuring myeloperoxidase activity. Curr Eye Res. 1982;2:465-470.
40. Box GEP, Cox DR. An analysis of transformations. J R Stat Soc Series B. 1964;26:211-252.
41. Box GEP, Hill WH. Correcting inhomogeneity of variance with power transformation weighting. Technometrics. 1974;16:385-389.
42. Rosen J, Miner JN. The search for safer glucocorticoid receptor ligands. Endocr Rev. 2005;26:452-464.
43. Bledsoe RK, Montana VG, Stanley TB, et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 2002;110:93-105.
44. Biggadike K, Bledsoe RK, Hassell AM, et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem. 2008;51:3349-3352.
45. Madauss KP, Bledsoe RK, McLay I, et al. The first X-ray crystal structure of the glucocorticoid receptor bound to a non-steroidal agonist. Bioorg Med Chem Lett. 2008;18:6097-6099.
46. Kauppi B, Jakob C, Farnegardh M, et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem. 2003;278: 22748-22754.
47. Coghlan MJ, Jacobson PB, Lane B, et al. A novel anti-inflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol. 2003;17:860-869.
48. Lo ́pez FJ, Ardecky RJ, Bebo B, et al. LGD-5552, an anti-inflammatory glucocorticoid receptor ligand with reduced side effects, in vivo. Endocrinology. 2008;149:2080-2089.
49. Gilson H, Schakman O, Combaret L, et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology. 2007;148:452-460.
50. Ma K, Mallidis C, Artaza J, Taylor W, Gonzalez-Cadavid N, Bhasin S. Characterization of 5'-regulatory region of human myostatin gene: regulation by dexamethasone in vitro. Am J Physiol Endocrinol Metab. 2001;281:E1128-E1136.
51. Ma K, Mallidis C, Bhasin S, et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab. 2003;285:E363-E371.
52. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631-639.
53. Yoshida A, Fujihara T, Nakata K. Cyclosporin A increases tear fluid secretion via release of sensory neurotransmitters and muscarinic pathway in mice. Exp Eye Res. 1999;68:541-546.
54. El-Shazly AH, El-Gohary AA, El-Shazly LH, El-Hossary GG. Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits. Acta Pharm. 2008;58: 163-173.
55. Scheib SA, Garner WH. Anti-inflammatory effects of topical ocular AXIDEX administration to rabbits following vitrectomy or lensectomy. Exp Eye Res. 2004;79:893-902.